Jul 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Melphalan flufenamide (Pepaxto) was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2021.

Immorna Biotherapeutics Gets U.S. FDA IND Approval for JCXH-211 IV Phase 1/2 Trial Alone and with Checkpoint Inhibitor in Advanced Solid Tumor Patients.

Casimersen was approved by the U.S. Food and Drug Administration (FDA) on February 25, 2021.

Mirum Pharmaceuticals, Inc. revealed that the European Commission has approved the marketing authorization for LIVMARLI® (maralixibat) oral solution

Trilaciclib was approved by the U.S. Food and Drug Administration (FDA) on February 12, 2021.

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that the European Commission has granted approval for Dupixent (dupilumab) as an additional maintenance therapy for adults with uncontrolled chronic obstructive pulmonary disease with elevated blood eosinophils.

Evinacumab was approved by the U.S. Food and Drug Administration (FDA) on February 11, 2021.

Cartesian Therapeutics, revealed that the initial patient has been treated in its Phase 2 open-label clinical study assessing Descartes-08 in individuals with systemic lupus erythematosus.

Lisocabtagene maraleucel received approval from the U.S. Food and Drug Administration (FDA) on February 5, 2021.

Checkpoint Therapeutics has announced the successful resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for cosibelimab.

Voclosporin was approved by the U.S. Food and Drug Administration (FDA) on January 22, 2021.